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Table 1: CONSORT 2010 checklist of information to include when reporting a cluster 
randomised trial  
Section/Topic Item 
No 
Standard Checklist item Extension for cluster 
designs 
Page 
No * 
Title and abstract  
 1a Identification as a 
randomised trial in the title 
Identification as a cluster 
randomised trial in the title 
1 
1b Structured summary of trial 
design, methods, results, and 
conclusions (for specific 
guidance see CONSORT for 
abstracts) 
See table 2 2 
Introduction  
Background and 
objectives 
2a Scientific background and 
explanation of rationale 
Rationale for using a cluster 
design 
3 
2b Specific objectives or 
hypotheses 
Whether objectives pertain to the 
the cluster level, the individual 
participant level or both 
3, 6 
Methods  
Trial design 3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio 
Definition of cluster and 
description of how the design 
features apply to the clusters 
3 
3b Important changes to 
methods after trial 
commencement (such as 
eligibility criteria), with 
reasons 
 n/a 
Participants 4a Eligibility criteria for 
participants 
Eligibility criteria for clusters  3-4 
4b Settings and locations where 
the data were collected 
 3 
Interventions 5 The interventions for each 
group with sufficient details 
to allow replication, 
including how and when they 
were actually administered 
Whether interventions pertain to 
the cluster level, the individual 
participant level or both 
4-5 
Outcomes 6a Completely defined pre-
specified primary and 
secondary outcome 
measures, including how and 
Whether outcome measures 
pertain to the  cluster level, the 
individual participant level or both 
3, 5-6 
when they were assessed 
6b Any changes to trial 
outcomes after the trial 
commenced, with reasons 
 n/a 
Sample size 7a How sample size was 
determined 
Method of calculation, number of 
clusters(s) (and whether equal or 
unequal cluster sizes are 
assumed), cluster size, a 
coefficient of intracluster 
correlation (ICC or k), and an 
indication of its uncertainty 
6 
7b When applicable, 
explanation of any interim 
analyses and stopping 
guidelines 
 n/a 
Randomisation:  
 Sequence 
generation 
8a Method used to generate the 
random allocation sequence 
 4 
8b Type of randomisation; 
details of any restriction 
(such as blocking and block 
size) 
Details of stratification or 
matching if used 
4 
 Allocation 
concealment 
mechanism 
9 Mechanism used to 
implement the random 
allocation sequence (such as 
sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until interventions 
were assigned 
Specification that allocation was 
based on clusters rather than 
individuals and whether allocation 
concealment (if any) was at the 
cluster level, the individual 
participant level or both 
4 
 Implementation 
 
10 Who generated the random 
allocation sequence, who 
enrolled participants, and 
who assigned participants to 
interventions 
Replace by 10a, 10b and 10c  
 10a  Who generated the random 
allocation sequence, who enrolled 
clusters, and who assigned 
clusters to interventions 
 
4 
 10b  Mechanism by which individual 
participants were included in 
clusters for the purposes of the 
trial (such as complete 
3-4 
enumeration, random sampling) 
 10c  From whom consent was sought 
(representatives of the cluster, or 
individual cluster members, or 
both), and whether consent was 
sought before or after 
randomisation 
 
4 
     
Blinding 11a If done, who was blinded 
after assignment to 
interventions (for example, 
participants, care providers, 
those assessing outcomes) 
and how 
 4 
11b If relevant, description of the 
similarity of interventions 
 n/a 
Statistical methods 12a Statistical methods used to 
compare groups for primary 
and secondary outcomes 
How clustering was taken into 
account 
6-7 
12b Methods for additional 
analyses, such as subgroup 
analyses and adjusted 
analyses 
 7 
Results  
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers 
of participants who were 
randomly assigned, received 
intended treatment, and 
were analysed for the 
primary outcome 
For each group, the numbers of 
clusters that were randomly 
assigned, received intended 
treatment, and were analysed for 
the primary outcome 
7, Fig 2 
13b For each group, losses and 
exclusions after 
randomisation, together with 
reasons 
For each group, losses and 
exclusions for both clusters and 
individual cluster members 
Fig 2 
Recruitment 14a Dates defining the periods of 
recruitment and follow-up 
 7 
14b Why the trial ended or was 
stopped 
 n/a 
Baseline data 15 A table showing baseline 
demographic and clinical 
Baseline characteristics for the 
individual and cluster levels as 
Table 1 
characteristics for each 
group 
applicable for each group 
Numbers analysed 16 For each group, number of 
participants (denominator) 
included in each analysis and 
whether the analysis was by 
original assigned groups 
For each group, number of 
clusters included in each analysis 
Figs 2-3  
Tables 2-4  
Outcomes and 
estimation 
17a For each primary and 
secondary outcome, results 
for each group, and the 
estimated effect size and its 
precision (such as 95% 
confidence interval) 
Results at the individual or cluster 
level as applicable and a 
coefficient of intracluster 
correlation (ICC or k) for each 
primary outcome 
 
Tables 2-4 
17b For binary outcomes, 
presentation of both 
absolute and relative effect 
sizes is recommended 
  
Ancillary analyses 18 Results of any other analyses 
performed, including 
subgroup analyses and 
adjusted analyses, 
distinguishing pre-specified 
from exploratory 
 Adjusted 
analysis for 
primary 
outcome in 
footnote of 
Table 2 
Harms 19 All important harms or 
unintended effects in each 
group (for specific guidance 
see CONSORT for harms1) 
 n/a 
Discussion  
Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses 
 9, 10 
Generalisability 21 Generalisability (external 
validity, applicability) of the 
trial findings 
Generalisability to clusters and/or 
individual participants (as 
relevant) 
9 
Interpretation 22 Interpretation consistent 
with results, balancing 
benefits and harms, and 
considering other relevant 
evidence 
 10 
Other information   
Registration 23 Registration number and  3 
name of trial registry 
Protocol 24 Where the full trial protocol 
can be accessed, if available 
 Reference 
number 18 
(referenced on 
page 6) 
Funding 25 Sources of funding and other 
support (such as supply of 
drugs), role of funders 
 7 
* Note: page numbers optional depending on journal requirements 
 
 
  
 Table 2:  Extension of CONSORT for abstracts to reports of cluster randomised trials 
 
Item Standard Checklist item Extension for cluster trials 
Title Identification of study as randomised Identification of study as cluster 
randomised 
Trial design Description of the trial design (e.g. parallel, 
cluster, non-inferiority) 
 
Methods   
Participants Eligibility criteria for participants and the 
settings where the data were collected 
Eligibility criteria for clusters  
Interventions Interventions intended for each group  
Objective Specific objective or hypothesis Whether objective or hypothesis pertains 
to the cluster level, the individual 
participant level or both 
Outcome Clearly defined primary outcome for this 
report 
Whether the primary outcome pertains to 
the cluster level, the individual participant 
level or both 
Randomization How participants were allocated to 
interventions 
How clusters were allocated to 
interventions 
Blinding (masking) Whether or not participants, care givers, 
and those assessing the outcomes were 
blinded to group assignment 
 
Results   
Numbers randomized Number of participants randomized to 
each group 
Number of clusters randomized to each 
group  
Recruitment Trial status1  
Numbers analysed Number of participants analysed in each 
group 
Number of clusters analysed in each 
group 
Outcome For the primary outcome, a result for each 
group and the estimated effect size and its 
precision 
Results at the cluster or individual 
participant level as applicable for each 
primary outcome 
Harms Important adverse events or side effects  
Conclusions General interpretation of the results   
Trial registration Registration number and name of trial 
register 
 
Funding Source of funding  
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